Development and characterization of a 177Lu-labeled anti-prostate stem cell antigen (PSCA) monoclonal antibody for metastatic prostate cancer

2019 ◽  
Vol 72-73 ◽  
pp. S20
Author(s):  
F. Striese ◽  
R. Bergmann ◽  
S. Weißflog ◽  
C. Arndt ◽  
A. Feldmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Monoclonal Antibody ◽  
Stem Cell ◽  
Metastatic Prostate Cancer ◽  
Prostate Stem Cell Antigen ◽  
Cell Antigen

scholarly journals Engineering A11 Minibody-Conjugated, Polypeptide-Based Gold Nanoshells for Prostate Stem Cell Antigen (PSCA)–Targeted Photothermal Therapy

2016 ◽  
Vol 22 (1) ◽  
pp. 26-35 ◽  
Author(s):  
Kristine M. Mayle ◽  
Kathryn R. Dern ◽  
Vincent K. Wong ◽  
Kevin Y. Chen ◽  
Shijun Sung ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Cancer Cells ◽  
Photothermal Therapy ◽  
Metastatic Prostate Cancer ◽  
Gold Nanoshells ◽  
Infrared Light ◽  
Prostate Stem Cell Antigen ◽  
Prostate Cancer Cells ◽  
Cell Antigen

Currently, there is no curative treatment for advanced metastatic prostate cancer, and options, such as chemotherapy, are often nonspecific, harming healthy cells and resulting in severe side effects. Attaching targeting ligands to agents used in anticancer therapies has been shown to improve efficacy and reduce nonspecific toxicity. Furthermore, the use of triggered therapies can enable spatial and temporal control over the treatment. Here, we combined an engineered prostate cancer–specific targeting ligand, the A11 minibody, with a novel photothermal therapy agent, polypeptide-based gold nanoshells, which generate heat in response to near-infrared light. We show that the A11 minibody strongly binds to the prostate stem cell antigen that is overexpressed on the surface of metastatic prostate cancer cells. Compared to nonconjugated gold nanoshells, our A11 minibody-conjugated gold nanoshell exhibited significant laser-induced, localized killing of prostate cancer cells in vitro. In addition, we improved upon a comprehensive heat transfer mathematical model that was previously developed by our laboratory. By relaxing some of the assumptions of our earlier model, we were able to generate more accurate predictions for this particular study. Our experimental and theoretical results demonstrate the potential of our novel minibody-conjugated gold nanoshells for metastatic prostate cancer therapy.

scholarly journals [89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model

2019 ◽  
Vol 22 (2) ◽  
pp. 367-376 ◽  
Author(s):  
Kirstin A. Zettlitz ◽  
Wen-Ting K. Tsai ◽  
Scott M. Knowles ◽  
Felix B. Salazar ◽  
Naoko Kobayashi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Human Prostate ◽  
Prostate Stem Cell Antigen ◽  
Cell Antigen ◽  
Syngeneic Model

Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter

The Prostate ◽  
2009 ◽  
Vol 69 (13) ◽  
pp. 1422-1434 ◽  
Author(s):  
Frank A. Petrigliano ◽  
Mandeep S. Virk ◽  
Nancy Liu ◽  
Osamu Sugiyama ◽  
Duan Yu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Cancer Cells ◽  
Lentiviral Vector ◽  
Prostate Stem Cell Antigen ◽  
Prostate Cancer Cells ◽  
Cell Antigen

scholarly journals Prostate Stem Cell Antigen DNA Vaccination Breaks Tolerance to Self-antigen and Inhibits Prostate Cancer Growth

2009 ◽  
Vol 17 (6) ◽  
pp. 1101-1108 ◽  
Author(s):  
Sarfraz Ahmad ◽  
Garrett Casey ◽  
Paul Sweeney ◽  
Mark Tangney ◽  
Gerald C O'Sullivan
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Dna Vaccination ◽  
Cancer Growth ◽  
Prostate Stem Cell Antigen ◽  
Cell Antigen ◽  
Self Antigen
Sign in / Sign up

Export Citation Format

Share Document